Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer

Li, Tong; Song, Rui; Wang, Jingjie; Zhang, Jianbo; Cai, Hongxing; He, Hao; Hu, Wei; Yu, Dajun; Wang, Chuanhu; Pan, Qingbo; Peng, Mingli; Ren, Hong; Zhu, Peng

doi:10.1016/j.ijid.2022.07.050

Cited by 3 publications

(5 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall seropositivity rate of anti-RBD-IgG and NAb in cancer patients was significantly lower than in healthy controls, and it was also lower than in previous studies of mRNA vaccines and inactivated vaccines ( 21 ), which could be attributed to the difference in vaccine type, cancer type, antibody testing kits, and interval time after full-course vaccination. Moreover, a continuously decay of antibody titers was observed with time in both ER cancer patients and healthy controls, which was similar to the results of previous longitudinal studies ( 17 , 22 , 23 ). Furthermore, the decrease in anti-RBD-IgG was particularly obvious in the cancer population; the results indicated that vaccine protection in patients with ER cancer may be weakened faster than in healthy controls.…”

Section: Discussionsupporting

confidence: 90%

“…Therefore, we first evaluated the short-term safety profile, and the results indicated that the overall incidence of AEs in patients with ER cancer within 7 days was similar to that of healthy controls, which was consistent with earlier studies ( 14 – 16 ). However, it was higher than our previous study in patients with gastrointestinal cancer (26.14% vs. 22.29%) ( 17 ), which suggests that different types of vaccines and cancers can contribute to this discrepancy. Furthermore, most of the AEs were mild and no vaccine-related serious AEs were reported in this study, which was consistent with earlier studies ( 9 , 18 , 19 ).…”

Section: Discussioncontrasting

confidence: 82%

“…Based on multiple linear regression, we found that a longer time after vaccination, a higher ASA score or TNM grade, and ongoing chemotherapy were adverse factors for worse antibody responses. A higher ASA or TNM grade usually indicated higher risks for anesthesia and poorer clinical conditions ( 17 ). Our findings were consistent with a previous study that found that cancer patients with poor ECOG PS (>2) had a higher chance of invalid vaccination ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundThe aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER).MethodsEighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated.ResultsApproximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time.ConclusionInactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussioncontrasting

confidence: 82%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Lastly, we found that the frequency of aytMBCs increased significantly over time after primary vaccination in AILD patients. AtyMBCs are short-lived activated cells with low binding to the spike protein of SARS-CoV-2 23 and was also increased in patients with common variable immunodeficiency, 42 solid tumors, 43 and severe liver diseases. 27 This indicated that the immune memory function was damaged over time in patients with AILD.…”

Section: Discussionmentioning

confidence: 99%

Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases

Chen,

Wang,

et al. 2023

J Clin Transl Hepatol

Self Cite

View full text Add to dashboard Cite

Background and Aims SARS-CoV-2 vaccines-associated autoimmune liver diseases have been reported in several case reports. However, the safety and immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in patients with autoimmune liver diseases (AILD) is still unknown. Methods Eighty-four patients with AILD were prospectively followed up after the second dose (primary) of inactivated SARS-CoV-2 vaccine. Some of them received the third dose (booster) of inactivated vaccine. Adverse events (AEs), autoimmune activation, and liver inflammation exacerbation after primary and booster vaccination were recorded. Meanwhile, dynamics of antireceptor-binding-domain IgG (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD-specific B cells responses were evaluated. Results The overall AEs in AILD patients after primary and booster vaccination were 26.2% and 13.3%, respectively. The decrease of C3 level and increase of immunoglobulin light chain κ and λ levels were observed in AILD patients after primary vaccination, however, liver inflammation was not exacerbated, even after booster vaccination. Both the seroprevalence and titers of anti-RBD-IgG and NAbs were decreased over time in AILD patients after primary vaccination. Notably, the antibody titers were significantly elevated after booster vaccination (10-fold in anti-RBD-IgG and 7.4-fold in NAbs, respectively), which was as high as in healthy controls. Unfortunately, the inferior antibody response was not enhanced after booster vaccination in patients with immunosuppressants. Changes of atypical memory B cells were inversely related to antibody levels, which indicate that the impaired immune memory was partially restored partly by the booster vaccination. Conclusions The well tolerability and enhanced humoral immune response of inactivated vaccine supports an additional booster vaccination in AILD patients without immunosuppressants.

show abstract

“…The efficacy of the conventional inactivated vaccination is often poor, and moderate side effects have been noted. 3 It would be interesting to discuss the safety of the more recent mRNA COVID-19 vaccines for cancer patients who have previously had COVID-19. If the participants' pre-existing immunological status is frequently evaluated, it is feasible to forecast the outcomes of receiving the COVID-19 immunization more accurately.…”

mentioning

confidence: 99%

COVID-19 Vaccination in Cancer Patients: Correspondence

Mungmunpuntipantip¹,

Wiwanitkit

2022

Cancer Control

View full text Add to dashboard Cite

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer

Cited by 3 publications

References 39 publications

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

Safety and Immunogenicity After Primary and Booster Inactivated SARS-Cov-2 Vaccination in Patients with Autoimmune Liver Diseases

COVID-19 Vaccination in Cancer Patients: Correspondence

Contact Info

Product

Resources

About